Literature DB >> 9426428

Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified?

O Gimm1, H Dralle.   

Abstract

BACKGROUND: Lymph node metastases (LNM) are very often found in medullary thyroid carcinoma. After primary therapy, elevated levels of calcitonin are measurable in many patients. Because of the low sensitivity and specificity of diagnostic tools to detect micrometastases, the question remains whether an extended lymphadenectomy improves the chance of cure and whether this approach should be tumor stage oriented.
METHODS: We analyzed the results of 36 patients with medullary thyroid carcinoma consecutively reoperated from 1988 to 1996, performing microdissection of all four locoregional lymph node compartments.
RESULTS: Pathologic tumor stage (pT) category was classified as pT1, n = 3; pT2 n = 22; pT3, n = 6; and pT4, n = 5. LNM were found in 34 patients (94%). The cervicocentral compartment contained LNM in 85%, the cervicolateral compartments in 41% to 54%, and the upper mediastinum in 36%. Patients with different pT category did not differ in the rate of LNM. Ipsilateral cervicolateral LNM were found in 50% to 71% and contralateral cervicolateral LNM in 14% to 40%. Nine (35%) of 26 patients without distant metastases were biochemically cured. In 10 patients (38%) calcitonin level decreased more than 50%.
CONCLUSIONS: LNM were almost always (94%) found in patients who have elevated calcitonin levels after primary therapy. In patients without distant metastases, four-compartment lymphadenectomy gives a chance of cure in 35%. A tumor stage-oriented approach does not seem to be justified.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426428     DOI: 10.1016/s0039-6060(97)90217-8

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 2.  [Reoperation for thyroid cancer].

Authors:  H Vogelsang; T Brückner; K Scheidhauer; M Schwaiger; J R Siewert
Journal:  Chirurg       Date:  2005-03       Impact factor: 0.955

Review 3.  Surgical strategy for the treatment of medullary thyroid carcinoma.

Authors:  J B Fleming; J E Lee; M Bouvet; P N Schultz; S I Sherman; R V Sellin; K E Friend; M A Burgess; G J Cote; R F Gagel; D B Evans
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

4.  [Lymphadenectomy for thyroid and lymph node carcinomas].

Authors:  O Gimm; H Dralle
Journal:  Chirurg       Date:  2007-03       Impact factor: 0.955

Review 5.  Medullary thyroid carcinoma--update and present management controversies.

Authors:  Mahir Al-Rawi; Malcolm H Wheeler
Journal:  Ann R Coll Surg Engl       Date:  2006-09       Impact factor: 1.891

Review 6.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

7.  Incidentally found medullary thyroid cancer: treatment rationale for small tumors.

Authors:  Andreas Raffel; Kenko Cupisti; Markus Krausch; Achim Wolf; Klaus-Martin Schulte; Hans-Dietrich Röher
Journal:  World J Surg       Date:  2004-03-04       Impact factor: 3.352

8.  Extent of surgery in clinically evident but operable MTC - when is central and/or lateral lympadenectomy indicated?

Authors:  Oliver Gimm
Journal:  Thyroid Res       Date:  2013-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.